According to Regeneron, the drug was under a priority review by the FDA, which is offered when a drug offers major advances in treatment or for a condition that has no adequate therapy. Two phase 3 clinical studies of almost 2,500 patients determined injection every two months after three initial monthly injections maintained or improved visual acuity equivalent to monthly doses of Lucentis.
Related Articles on Ophthalmology:
10 Recent Findings on Ophthalmology
Surgery Devices, Minimally Invasive Procedures to Drive the Ophthalmic Surgery Market
Report: Vision Problems Decline in People With Diabetes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.